Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05438667 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TCR-T Cell Therapy on Advanced Solid Tumors

StatusTerminated
PhaseEarly Phase 1
Started2023-06-01
View on ClinicalTrials.gov ↗
Why the trial stopped
In light of the impending acquisition of the project partner, Shanghai Bintie Biotechnology Co., Ltd., the company has resolved to close all IT centers and discontinue the clinical research project.
The primary aim of this study is to evaluate the efficacy of KRAS mutant antigen specific TCR-T cells in the treatment of patients with advanced solid tumors. The secondary aim is to evaluate the pharmacokinetic/pharmacodynamic characteristics of TCR-T cell therapy in patients with advanced solid tumors and the survival of TCR-T cells. The investigators will evaluate the changes of tumor microenvironment after treatment of advanced solid tumors with KRAS mutant antigen specific TCR-T cells; Evaluating the correlation between cytokines and the occurrence of CRS and neurotoxicity

Amendment history 3 changes detected by DataLookout

2026-09-02
Trial terminated: In light of the impending acquisition of the project partner, Shanghai Bintie Biotechnology Co., Ltd., the company has...
2026-09-02
Final enrollment: 1 participants — 6% of the 18 planned
2026-09-02
Primary completion confirmed: June 2026 (last estimated June 2028)
Trial Details
NCT Number NCT05438667
Lead Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions Pancreatic Cancer
Enrollment 1 participants
Start Date 2023-06-01
Primary Completion 2026-06-16 (estimated)
Study Completion 2026-06-16 (estimated)
Updated on ClinicalTrials.gov 2026-09-01